However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck (MRK) ended the recent trading session at $78.27, demonstrating a +1.46% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for the ...

To confirm the bearish trend, MRK has traded below its 200-day moving average since late July. The stock has been trading below its 50-day moving average since late June, with slight fluctuations.

Additionally, the successful launch of the antiviral pill, Lagevrio, has significantly bolstered the company's stock performance over the past two years. Merck's recent acquisition of Prometheus ...

Merck's unimpressive or nonexistent revenue growth (its top line declined in the first quarter) may be one of the reasons behind the company's poor stock market performance so far this year.

MRK stock YTD performance (as of 10 November 21). MRK stock started the year very poorly as it dropped into the red from almost the get-go. It stayed underwater throughout the year until it ...

and AbbVie stock (up 15%), Merck’s stock performance has been muted. This is attributed to declining sales of its blockbuster HPV vaccine – Gardasil – and an increased competition for some ...

Merck's market-beating performance has been fueled by the meteoric ... from generic biologics in the U.S. in 2028. Is Merck stock still a buy with this pivotal headwind looming?